Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2

Studies have shown that a subgroup of tumor cells possess stemness characteristics having self‐renewal capacity and the ability to form new tumors. We sought to identify the plausible stemness factor that determines the “molecular signature” of prostate cancer (PCa) cells derived from different metastases (PC3, PCa2b, LNCaP, and DU145) and whether androgen receptor (AR) influences the maintenance of stemness features. Here we show sex‐determining region Y (SRY)‐box 2 (SOX2) as a putative stem cell marker in PC3 PCa cells and not in DU145, PCa2b, or LNCaP cells. PCa2b and PC3 cells were derived from bone metastases. PCa2b cells which are positive for the AR failed to demonstrate the expression of either cluster of differentiation 44 (CD44) or SOX2. Knockdown (KD) of AR in these cells did not affect the expression of either CD44 or SOX2. Conversely, PC3 cells, which are negative for AR, expressed both CD44 and SOX2. However, the expression of AR downregulated the expression of both CD44 and SOX2 in PC3 cells. CD44 regulates SOX2 expression as KD of CD44 and reduces SOX2 levels considerably. SOX2 KD attenuated not only the expression of SNAIL and SLUG but also the migration and tumorsphere formation in PC3 cells. Collectively, our findings underscore a novel role of CD44 signaling in the maintenance of stemness and progression of cancer through SOX2 in AR‐independent PC3 cells. SOX2 has a role in the regulation of expression of SNAIL and SLUG. SOX2 could be a potential therapeutic target to thwart the progression of SOX2‐positive cancer cells or recurrence of androgen‐independent PCa.

[1]  Dahong Zhang,et al.  The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study , 2018, The Prostate.

[2]  A. Abernethy,et al.  Treatment dynamics of bone‐targeting agents among men with bone metastases from prostate cancer in the United States , 2018, Pharmacoepidemiology and drug safety.

[3]  Linda T. Senbanjo,et al.  CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells , 2017, Front. Cell Dev. Biol..

[4]  Q. Hu,et al.  NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis , 2016, Cell Discovery.

[5]  A. S. Nateri,et al.  Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon Cancer , 2016, Stem Cell Reviews and Reports.

[6]  J. Vadgama,et al.  Epithelial-Mesenchymal Transition and Breast Cancer , 2016, Journal of clinical medicine.

[7]  K. Kimata,et al.  Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells , 2015, Front. Oncol..

[8]  A. Zoubeidi,et al.  Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. , 2015, Endocrine-related cancer.

[9]  Seok-Jun Kim,et al.  Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer , 2015, Oncotarget.

[10]  V. Adhami,et al.  Role of epithelial mesenchymal transition in prostate tumorigenesis. , 2015, Current pharmaceutical design.

[11]  Steven Kregel,et al.  The pluripotency factor Nanog is directly upregulated by the Androgen Receptor in prostate cancer cells , 2014, The Prostate.

[12]  T. Sugihara,et al.  Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer , 2014, Clinical Cancer Research.

[13]  R. Xiang,et al.  SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/β-catenin signal network. , 2013, Cancer letters.

[14]  W. Bamlet,et al.  SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells , 2013, Oncogenesis.

[15]  I. Thompson,et al.  Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer , 2013, The Prostate.

[16]  Pang-Kuo Lo,et al.  In vitro Tumorsphere Formation Assays. , 2013, Bio-protocol.

[17]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[18]  Kyle J. Kiriluk,et al.  Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer , 2013, PloS one.

[19]  Aditi Gupta,et al.  Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis , 2012, Molecular Cancer.

[20]  A. Rizzino,et al.  Elevating SOX2 Levels Deleteriously Affects the Growth of Medulloblastoma and Glioblastoma Cells , 2012, PloS one.

[21]  L. Hood,et al.  Silencing SOX2 Induced Mesenchymal-Epithelial Transition and Its Expression Predicts Liver and Lymph Node Metastasis of CRC Patients , 2012, PloS one.

[22]  O. Brawley Prostate cancer epidemiology in the United States , 2012, World Journal of Urology.

[23]  A. Pandiella,et al.  Sox2 expression in breast tumours and activation in breast cancer stem cells , 2012, Oncogene.

[24]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[25]  Li Li,et al.  Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. , 2012, Cancer research.

[26]  Deepak Mav,et al.  The Transcription Factors Snail and Slug Activate the Transforming Growth Factor-Beta Signaling Pathway in Breast Cancer , 2011, PloS one.

[27]  R. Xiang,et al.  SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. , 2011, Journal of molecular cell biology.

[28]  Andrew J Armstrong,et al.  Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011 .

[29]  R. Markwald,et al.  Hyaluronan–CD44 interactions as potential targets for cancer therapy , 2011, The FEBS journal.

[30]  Zhiwei Wang,et al.  Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells , 2010, PloS one.

[31]  J. Thiery [Epithelial-mesenchymal transitions in cancer onset and progression]. , 2009, Bulletin de l'Academie nationale de medecine.

[32]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[33]  H. Ford,et al.  Epithelial-mesenchymal transition in development and cancer. , 2009, Future oncology.

[34]  T. Ma,et al.  Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface , 2009, Journal of cellular biochemistry.

[35]  C. Takimoto,et al.  Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.

[36]  Lesley A. Mathews,et al.  Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature , 2009, Clinical & Experimental Metastasis.

[37]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[38]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[39]  M. Rogers,et al.  Molecular Cancer Mechanisms of Osteopontin and Cd44 as Metastatic Principles in Prostate Cancer Cells , 2006 .

[40]  M. Götte,et al.  Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.

[41]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[42]  T. Golub,et al.  Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells , 2004, Cancer Research.

[43]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Balk,et al.  Androgen receptor as a target in androgen-independent prostate cancer. , 2002, Urology.

[45]  L. Chung,et al.  Regulation of Human Osteocalcin Promoter in Hormone-independent Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[46]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[47]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[48]  K. Chan,et al.  Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames , 1999, The Prostate.

[49]  D. Johnston,et al.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[51]  K. Hruska,et al.  Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. , 1996, Molecular biology of the cell.

[52]  R. Midura,et al.  Expression of CD44 isoforms in human prostate tumor cell lines , 1996, The Prostate.

[53]  D. S. Coffey,et al.  Control of prostate growth. , 1981, Urology.

[54]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[55]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.